VERTIROTRAVEL 50 mg sublingual tablets are an effective medicine for the prevention and treatment of travel sickness. The active ingredient dimenhydrinate is effective against nausea, vomiting and dizziness.
€5.15*
Prices incl. VAT plus shipping costs (May vary by country)
Ready to ship in 1-3 working days ⁴
VERTIROTRAVEL 50 mg sublingual tablets are an effective medicine for the prevention and treatment of travel sickness. The active ingredient dimenhydrinate is effective against nausea, vomiting and dizziness.
Dimenhydrinate, the active ingredient in Vertirotravel, is a long-established remedy for travel sickness. Dimenhydrinate is an active ingredient from the group of antihistamines. It interferes with nerve circuits that transmit impulses - including those from the balance organ in the inner ear - to the vomiting centre, thereby suppressing or alleviating the typical symptoms of travel sickness (e.g. dizziness, nausea and vomiting).
Vertirotravel is used to prevent and treat travel sickness. The medication is administered sublingually, i.e. you place it under the tongue until it dissolves without water. With this dosage form, it is no longer necessary to swallow a tablet if nausea is already present. The first dose should be taken at least 30 - 60 minutes before travelling.
Suitable for use in adults, adolescents and children over 12 years of age. For the prevention and treatment of travel sickness in children aged 2 - 12 years, consult your doctor.
Dosage form
tablets
How to use
- The recommended dose is: 50 mg to 100 mg (1-2 sublingual tablets), 3 or 4 times daily. The first dose should be taken at least 30 to 60 minutes before travelling. The maximum dose is 8 tablets per day.
- The maximum dose is 400 mg per day.
- Route of administration: This medicine is to be taken sublingually (by placing it under the tongue until it dissolves without water). Do not chew or swallow.
Ingredients
- The active substance is: dimenhydrinate. Each sublingual tablet contains 50 mg dimenhydrinate.
- The other ingredients are: Microcrystalline cellulose, mannitol, methacrylic acid-methyl methacrylate copolymer (Eudragit L100), sodium starch glycolate - type A, vanilla flavour, saccharin, highly dispersed anhydrous silicon dioxide, magnesium stearate, levomenthol, talc.
| Piece: | 4 |
|---|
Instructions for use
| Type of use: | Sublingual ohne Wasser nach den Mahlzeiten Nicht kauen oder schlucken |
|---|---|
| Field of use: | Vorbeugung und Behandlung von Reisekrankheit |
| Dosage: | Personen ab 12 Jahren Ab 45kg bis 56kg KG 3mal tgl 50 - 100 mg = 1-2 Tbl MTD 300 mg Ab 56kg KG 3-4mal tgl 50 - 100 mg = 1-2 Tbl MTD 400 mg Zur Vorbeugung 1 Dosis mind 30-60 min vor der Reise, Wiederholung während Fahrt möglich Nicht |
| Properties and efficacy: | Hsub1sub-Antihistaminikum; antiemetisch, peripher anticholinerg |
| Contraindications: | LogImport.sisx.GAD.Akutes Asthma, Phäochromozytom, Krämpfe, Risiko für Engwinkelglaukom oder Harnverhaltung, Herzrhythmusstörungen |
| Side effects: | Kopfschmerz, erhöhter Augeninnendruck, ZNS Schläfrigkeit, Sedierung, anticholinerg, Blutbild |
| Special warnings for safe use: | Vorsicht bei Zuständen, die durch Anticholinergika verstärkt werden können zB erhöhter Augeninnendruck, Hypertonie, M Parkinson, orthostatischer Hypotonie, schweren Leber- oder Nierenschäden Verkehrshinweis |
| Interactions: | Alkohol, QT-verlängernde Substanzen meiden Vorsicht Anticholinergika, ZNS-Dämpfer, Aminoglykoside Ototoxizität, CYP2D6-Substrate mit enger therap Breite, MAO-Hemmer, Sympathomimetika verstärkt |
| Pregnancy and breastfeeding period: | Strenge NutzenRisiko-Abwägung im 1 und 2 Trimenon; im 3 Trimenon und in der Stillzeit nicht anwenden |
Pregnancy information
| Use forbidden |
|---|
| Use only if absolutely or vitally indicated |
Breastfeeding information
| Breastfeeding forbidden |
|---|
Pictograms
| Take with meals |
|---|
| Caution: may affect ability to drive/use machines |
| Avoid alcohol intake |